Septerna (NASDAQ:SEPN) Coverage Initiated at TD Cowen

Research analysts at TD Cowen started coverage on shares of Septerna (NASDAQ:SEPN) in a note issued to investors on Tuesday, Marketbeat reports. The firm set a “buy” rating on the stock.

Septerna Stock Down 7.0 %

NASDAQ:SEPN opened at $22.50 on Tuesday. Septerna has a 1-year low of $18.62 and a 1-year high of $26.34.

Insider Buying and Selling at Septerna

In other news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the firm’s stock in a transaction on Monday, October 28th. The shares were bought at an average price of $18.00 per share, for a total transaction of $6,669,000.00. Following the purchase, the insider now owns 6,215,591 shares in the company, valued at approximately $111,880,638. The trade was a 6.34 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.